Tranilast reduces serum IL-6 and IL-13 and protects against thioacetamide-induced acute liver injury and hepatic encephalopathy

Abdеlaziz, Rania R.; Elkashef, Wagdi; Said, Eman

doi:10.1016/j.etap.2015.06.019

Cited by 32 publications

(17 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In rats, the tranilast and methylprednisolone combination therapy has exhibited an effective anti‐inflammation function during acute spinal cord injury . Tranilast administration also reduced the serum levels of IL‐6 and IL‐13 in rats, which protected the rats from acute liver injury and hepatic encephalopathy . However, the role of tranilast in neuronal systems remains poorly understood.…”

Section: Discussionmentioning

confidence: 99%

“…19 Tranilast administration also reduced the serum levels of IL-6 and IL-13 in rats, which protected the rats from acute liver injury and hepatic encephalopathy. 20 However, the role of tranilast in neuronal systems remains poorly understood. IRI is one of the leading causes of the disability and death in patients after stroke, cerebral infarction, or organ transplantation.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Tranilast Treatment Attenuates Cerebral Ischemia‐Reperfusion Injury in Rats Through the Inhibition of Inflammatory Responses Mediated by NF‐κB and PPARs

Yang

Zhuo

2018

Clinical Translational Sci

View full text Add to dashboard Cite

Ischemia‐reperfusion injury ( IRI ) occurs when blood supply returns to tissue after interruption, which is associated with life‐threatening inflammatory response. Tranilast is a widely used antiallergic agent in the treatment against bronchial asthma and keloid. To study the function of tranilast, we used IRI in rat models. The brain tissues of IRI rats with or without tranilast treatment were collected. Neuronal apoptosis in the brain was detected by terminal deoxynucleotidyl transferase nick end labeling assay, and proinflammatory cytokine levels were measured by quantitative real‐time polymerase chain reaction and enzyme‐linked immunosorbent assay. The expression levels of nuclear factor‐kappa B ( NF ‐κB), inhibitor of κB (IκB) and peroxisome proliferator‐activated receptors ( PPAR s) were detected by Western blot. The results showed that tranilast treatment reduced neuronal apoptosis in the brain of IRI rats. Tranilast enhanced the short‐term memory and long‐term memory to novel object recognition paradigm. Tranilast treatment decreased the messenger RNA ( mRNA ) and protein levels of multiple proinflammatory cytokines, and affected NF ‐κB and inhibitor of kappa B protein expressions. Tranilast promoted the expressions of PPAR ‐α and PPAR ‐γ. Our findings demonstrate that tranilast treatment could attenuate cerebral IRI by regulating the inflammatory cytokine production and PPAR expression. Tranilast is a potential drug for IRI treatment in the clinic.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Tranilast Treatment Attenuates Cerebral Ischemia‐Reperfusion Injury in Rats Through the Inhibition of Inflammatory Responses Mediated by NF‐κB and PPARs

Yang

Zhuo

2018

Clinical Translational Sci

View full text Add to dashboard Cite

show abstract

“…This experimental model mimics the physiopathogenic and pathophysiological aspects of the disease in humans and helps in the understanding of its progress and the possibility of therapeutic intervention [16,[27][28][29].…”

Section: Resultsmentioning

confidence: 99%

Action of Melatonin on Severe Acute Liver Failure in Rats

Salvi¹,

Schemitt²,

Colares³

et al. 2017

IOSRJPBS

View full text Add to dashboard Cite

Abstract:Severe acute liver failure (ALF) manifests itself as a rare syndrome, with multiple etiologies for similar clinical conditions. Melatonin (MLT) is a lipophilic indolamine that is synthesized in the pineal gland from serotonin. This study was designed to evaluate hepatic changes resulting from the thioacetamide-induced ALF model, as well as the effects of MLT treatment in male Wistar rats (n = 56) in 24-and 48-h experiments. The results indicate a hepatoprotective effect of MLT, with no difference between the studied times, and increased animal survival.

show abstract

“…Conversely, Abdelaziz et al. (2015) found that a reduction in IL‐6 prevents thioacetamide‐induced acute liver injury and hepatic encephalopathy .…”

mentioning

confidence: 99%

“…Li et al (2016) reported that IL-6 protects against acute liver injury induced by acetaminophen in mice (12). Conversely, Abdelaziz et al (2015) found that a reduction in IL-6 prevents thioacetamideinduced acute liver injury and hepatic encephalopathy (13).…”

mentioning

confidence: 99%

IL‐2/IL‐6 ratio correlates with liver function and recovery in acute liver injury patients

Sun

Liu

et al. 2019

APMIS

View full text Add to dashboard Cite

Acute liver injury can result from a number of different diseases. Inflammatory cytokines are known to be involved in the development of this condition; however, their precise roles and effects on liver function remain unclear. The goal of this study was to determine the relationship between serum cytokine levels and both the severity of liver damage and recovery in acute liver injury. We enrolled 100 patients with acute liver injury caused by drug application who were hospitalized from September 2012 to September 2017 and measured serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and the cytokines, interleukin (IL)‐2 and IL‐6, before and after clinical therapy. Our results indicate that IL‐2 and IL‐6 levels are altered significantly following clinical therapy. However, with the exception of an association between IL‐2 and ALT, we found no correlation between the differences in cytokine levels pre‐ and post‐therapy and recovery of liver function. In contrast, we observed that pre‐ vs post‐treatment difference in the IL‐2/IL‐6 ratio negatively correlates with the pre‐ vs post‐treatment difference in ALT and AST values, and positively correlates with ALT and AST at 1‐month post‐discharge. Thus, our data suggest that IL‐2/IL‐6 ratio may represent a novel predictor for the prognosis of liver injury.

show abstract

Tranilast reduces serum IL-6 and IL-13 and protects against thioacetamide-induced acute liver injury and hepatic encephalopathy

Cited by 32 publications

References 38 publications

Tranilast Treatment Attenuates Cerebral Ischemia‐Reperfusion Injury in Rats Through the Inhibition of Inflammatory Responses Mediated by NF‐κB and PPARs

Tranilast Treatment Attenuates Cerebral Ischemia‐Reperfusion Injury in Rats Through the Inhibition of Inflammatory Responses Mediated by NF‐κB and PPARs

Action of Melatonin on Severe Acute Liver Failure in Rats

IL‐2/IL‐6 ratio correlates with liver function and recovery in acute liver injury patients

Contact Info

Product

Resources

About